LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Suicidality and psychotic episodes after starting aripiprazole: two case reports.

    Meyer, Guillaume / Gitahy Falcao Faria, Clara / Beck, Marine / Riutort, Marielle / Michel, Bruno / Javelot, Hervé

    International clinical psychopharmacology

    2022  Volume 37, Issue 5, Page(s) 225–228

    Abstract: Switching antipsychotic medication must be done carefully to ensure patient safety and a successful response. Here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. Mr. X ... ...

    Abstract Switching antipsychotic medication must be done carefully to ensure patient safety and a successful response. Here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. Mr. X was treated with paliperidone and experienced residual anxiety. Thus, a switch to aripiprazole was planned with risperidone and a gradual decrease in paliperidone. Initially, an increase in aripiprazole resulted in remission of his residual symptoms. However, two weeks later, he presented an anxiety relapse with persecutory ideas which required hospitalization. Mr. Y, who was treated for many years with risperidone, presented with a treatment resistant psychotic episode. A switch to aripiprazole enhanced his clinical condition. Despite the initial improvement, soon after discharge from the hospital, the patient presented psychotic symptoms requiring home intervention. Ultimately, the patient in the midst of a delusional recrudescence, had killed himself when the health care team arrived. A strong dopamine antagonist may lead to the development of dopaminergic upregulation. The addition of a partial agonist to these hypersensitive neurotransmitter pathways could explain these episodes. We agree with previous reports and recommend careful management when switching from strong dopamine antagonists to aripiprazole.
    MeSH term(s) Antipsychotic Agents/adverse effects ; Aripiprazole/adverse effects ; Humans ; Male ; Paliperidone Palmitate ; Risperidone/adverse effects ; Suicide
    Chemical Substances Antipsychotic Agents ; Aripiprazole (82VFR53I78) ; Risperidone (L6UH7ZF8HC) ; Paliperidone Palmitate (R8P8USM8FR)
    Language English
    Publishing date 2022-06-02
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 632837-4
    ISSN 1473-5857 ; 0268-1315
    ISSN (online) 1473-5857
    ISSN 0268-1315
    DOI 10.1097/YIC.0000000000000408
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?

    Gitahy Falcao Faria, Clara / Weiner, Luisa / Petrignet, Julien / Hingray, Coraline / Ruiz De Pellon Santamaria, Ángel / Villoutreix, Bruno O / Beaune, Philippe / Leboyer, Marion / Javelot, Hervé

    Medical hypotheses

    2021  Volume 148, Page(s) 110508

    Abstract: Several studies have reported that certain psychoactive drugs could have a protective effect against SARS-CoV-2. Herein, we propose that antihistamines (anti-H1) and cationic amphiphilic drugs (CAD), specifically, have the capacity to disrupt virus entry ...

    Abstract Several studies have reported that certain psychoactive drugs could have a protective effect against SARS-CoV-2. Herein, we propose that antihistamines (anti-H1) and cationic amphiphilic drugs (CAD), specifically, have the capacity to disrupt virus entry and replication. In addition, several of these molecules have limited side effects and as such could be promising prophylactic candidates against SARS-CoV-2 infection.
    MeSH term(s) COVID-19/drug therapy ; COVID-19/virology ; Drug Repositioning ; Histamine H1 Antagonists/pharmacology ; Humans ; Models, Biological ; Pandemics ; SARS-CoV-2/drug effects ; SARS-CoV-2/physiology ; Surface-Active Agents/pharmacology ; Virus Internalization/drug effects ; Virus Replication/drug effects
    Chemical Substances Histamine H1 Antagonists ; Surface-Active Agents
    Language English
    Publishing date 2021-01-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2021.110508
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: My Health Too: Investigating the Feasibility and the Acceptability of an Internet-Based Cognitive-Behavioral Therapy Program Developed for Healthcare Workers.

    Bureau, Raven / Bemmouna, Doha / Faria, Clara Gitahy Falcao / Goethals, Anne-Aline Catteau / Douhet, Floriane / Mengin, Amaury C / Fritsch, Aurélie / Zinetti Bertschy, Anna / Frey, Isabelle / Weiner, Luisa

    Frontiers in psychology

    2021  Volume 12, Page(s) 760678

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2021-12-03
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2563826-9
    ISSN 1664-1078
    ISSN 1664-1078
    DOI 10.3389/fpsyg.2021.760678
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology.

    Javelot, Hervé / Gitahy Falcao Faria, Clara / Vandenberghe, Frederik / Dizet, Sophie / Langrée, Bastien / Le Maout, Mathilde / Straczek, Céline / Egron, Adeline / Erb, Alexis / Sujol, Guillaume / Yrondi, Antoine / Weibel, Sébastien / Vincent, Philippe D / Meyer, Guillaume / Hingray, Coraline

    Pharmacy (Basel, Switzerland)

    2021  Volume 9, Issue 3

    Abstract: Although clinical pharmacy is a discipline that emerged in the 1960s, the question of precisely how pharmacists can play a role in therapeutic optimization remains unanswered. In the field of mental health, psychiatric pharmacists are increasingly ... ...

    Abstract Although clinical pharmacy is a discipline that emerged in the 1960s, the question of precisely how pharmacists can play a role in therapeutic optimization remains unanswered. In the field of mental health, psychiatric pharmacists are increasingly involved in medication reconciliation and therapeutic patient education (or psychoeducation) to improve medication management and enhance medication adherence, respectively. However, psychiatric pharmacists must now assume a growing role in team-based models of care and engage in shared expertise in psychopharmacology in order to truly invest in therapeutic optimization of psychotropics. The increased skills in psychopharmacology and expertise in psychotherapeutic drug monitoring can contribute to future strengthening of the partnership between psychiatrists and psychiatric pharmacists. We propose a narrative review of the literature in order to show the relevance of a clinical pharmacist specializing in psychiatry. With this in mind, herein we will address: (i) briefly, the areas considered the basis of the deployment of clinical pharmacy in mental health, with medication reconciliation, therapeutic education of the patient, as well as the growing involvement of clinical pharmacists in the multidisciplinary reflection on pharmacotherapeutic decisions; (ii) in more depth, we present data concerning the use of therapeutic drug monitoring and shared expertise in psychopharmacology between psychiatric pharmacists and psychiatrists. These last two points are currently in full development in France through the deployment of Resource and Expertise Centers in PsychoPharmacology (CREPP in French).
    Language English
    Publishing date 2021-08-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2737194-3
    ISSN 2226-4787 ; 2226-4787
    ISSN (online) 2226-4787
    ISSN 2226-4787
    DOI 10.3390/pharmacy9030146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Negative Affect Mediates Impulsivity in Generalized Anxiety Disorder.

    Ferreira-Garcia, Rafael / Gitahy Falcão Faria, Clara / Nardi, Antonio Egídio / da Rocha Freire, Rafael Christophe

    Psychopathology

    2020  Volume 52, Issue 6, Page(s) 327–333

    Abstract: Introduction: Although anxiety and impulsivity are intuitively thought to be inversely correlated, increased impulsivity has been associated both with generalized anxiety disorder (GAD) diagnosis and GAD symptoms in non-clinical samples. The emotional ... ...

    Abstract Introduction: Although anxiety and impulsivity are intuitively thought to be inversely correlated, increased impulsivity has been associated both with generalized anxiety disorder (GAD) diagnosis and GAD symptoms in non-clinical samples. The emotional dysregulation model of GAD posits that patients experience more frequent and intense negative emotions while having poor regulatory control over emotional states and greater negative reactivity to their emotions. We hypothesized that poor regulatory control in the presence of negative emotions might explain the increased impulsivity found in GAD patients. In this study, we examined if negative affect mediates the relationship between GAD and impulsivity.
    Methods: Thirty-four GAD patients and 35 healthy controls were included, and evaluated with measurements of impulsivity, negative and positive emotions, the severity of worrying and GAD symptoms, depression, and 5-factor personality traits.
    Results: Global impulsivity scores and the attentional facet of impulsivity were higher in the patient group when compared to the controls. Negative affect was correlated with global impulsivity in the patient group only and explained impulsivity in our regression model while worrying and depressive symptoms did not. An indirect relationship was found between diagnosis and impulsivity through negative affect.
    Conclusion: Our study showed that the cardinal symptom of GAD - worrying - was not independently related to impulsivity in our sample. Increased impulsivity in GAD seems to be mediated by the increased presence of negative emotions, as it is common in mood and impulse-control disorders, indicating an unspecific shared vulnerability factor to psychopathology.
    MeSH term(s) Adult ; Anxiety Disorders/psychology ; Case-Control Studies ; Emotions/physiology ; Female ; Humans ; Impulsive Behavior/physiology ; Male
    Language English
    Publishing date 2020-01-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 605604-0
    ISSN 1423-033X ; 0254-4962
    ISSN (online) 1423-033X
    ISSN 0254-4962
    DOI 10.1159/000503395
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Understanding and addressing COVID-19 vaccine hesitancy in low and middle income countries and in people with severe mental illness: Overview and recommendations for Latin America and the Caribbean.

    Faria, Clara Gitahy Falcão / de Matos, Ursula Medeiros Araujo / Llado-Medina, Liana / Pereira-Sanchez, Victor / Freire, Rafael / Nardi, Antonio Egidio

    Frontiers in psychiatry

    2022  Volume 13, Page(s) 910410

    Abstract: Despite the speedy development of vaccines for COVID-19, their rollout has posed a major public health challenge, as vaccine hesitancy (VH) and refusal are high. Addressing vaccine hesitancy is a multifactorial and context-dependent challenge. This ... ...

    Abstract Despite the speedy development of vaccines for COVID-19, their rollout has posed a major public health challenge, as vaccine hesitancy (VH) and refusal are high. Addressing vaccine hesitancy is a multifactorial and context-dependent challenge. This perspective focuses on VH in the world region of Latin America and the Caribbean (LAC) and includes people suffering from severe mental illness, therefore covering populations and subpopulations often neglected in scientific literature. We present an overview of VH in LAC countries, discussing its global and historical context. Vaccine uptake has shown to widely vary across different subregions of LAC. Current data points to a possible correlation between societal polarization and vaccination, especially in countries going through political crises such as Brazil, Colombia, and Venezuela. Poor accessibility remains an additional important factor decreasing vaccination rollout in LAC countries and even further, in the whole Global South. Regarding patients with severe mental illness in LAC, and worldwide, it is paramount to include them in priority groups for immunization and monitor their vaccination coverage through public health indicators.
    Language English
    Publishing date 2022-09-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2022.910410
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: A Brazilian Case of Treatment-Resistant Generalized Anxiety Disorder Successfully Treated with Monoamine Oxidase Inhibitor (MAOI).

    Faria, Clara Gitahy Falcão / Fidry, Marcos / do Cabo, Mariana Costa / Quagliato, Laiana Azevedo / Nardi, Antonio Egidio / Zaman, Rashid / Freire, Rafael

    Psychiatria Danubina

    2020  Volume 32, Issue Suppl 1, Page(s) 139–141

    Abstract: In this brief report we present the case of a 53 year old man with a very debilitating Generalized Anxiety Disorder successfully treated with tranylcypromine. After several failed treatment attempts following international guidelines recommendations over ...

    Abstract In this brief report we present the case of a 53 year old man with a very debilitating Generalized Anxiety Disorder successfully treated with tranylcypromine. After several failed treatment attempts following international guidelines recommendations over the course of one year and a half, tranylcypromine was prescribed which led to effective and sustained remission of anxiety symptoms for this patient. We also briefly explore treatment options for resistant cases of generalized anxiety disorder, given the major negative impacts of untreated GAD in a person's daily functioning and quality of life.
    MeSH term(s) Anxiety ; Anxiety Disorders/drug therapy ; Drug Therapy, Combination ; Humans ; Male ; Middle Aged ; Monoamine Oxidase Inhibitors/therapeutic use ; Quality of Life
    Chemical Substances Monoamine Oxidase Inhibitors
    Keywords covid19
    Language English
    Publishing date 2020-09-05
    Publishing country Croatia
    Document type Case Reports ; Journal Article
    ZDB-ID 1067580-2
    ISSN 0353-5053
    ISSN 0353-5053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: A Brazilian Case of Treatment-Resistant Generalized Anxiety Disorder Successfully Treated with Monoamine Oxidase Inhibitor (MAOI)

    Faria, Clara Gitahy Falcão / Fidry, Marcos / do Cabo, Mariana Costa / Quagliato, Laiana Azevedo / Nardi, Antonio Egidio / Zaman, Rashid / Freire, Rafael

    Psychiatr Danub

    Abstract: In this brief report we present the case of a 53 year old man with a very debilitating Generalized Anxiety Disorder successfully treated with tranylcypromine. After several failed treatment attempts following international guidelines recommendations over ...

    Abstract In this brief report we present the case of a 53 year old man with a very debilitating Generalized Anxiety Disorder successfully treated with tranylcypromine. After several failed treatment attempts following international guidelines recommendations over the course of one year and a half, tranylcypromine was prescribed which led to effective and sustained remission of anxiety symptoms for this patient. We also briefly explore treatment options for resistant cases of generalized anxiety disorder, given the major negative impacts of untreated GAD in a person's daily functioning and quality of life.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32890377
    Database COVID19

    Kategorien

To top